Skip to main content
SpringerLink
Log in

The Economic Impact of Once-Daily versus Conventional Administration of Gentamicin and Tobramycin

  • Original Research Article
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

Summary

This retrospective, observational study was designed to compare once-daily with conventional aminoglycoside administration for costs while determining equivalency in efficacy and toxicity.

100 consecutive patients who had been treated with once-daily aminoglycosides after 1st August 1993, were evaluated via retrospective chart review. For comparison, 100 consecutive patients who were treated with conventional regimens of aminoglycosides, over the same calender period 1 year earlier (beginning on 1st August 1992), were evaluated in a similar manner. Aminoglycoside antibacterials, excluding amikacin, were administered as a single daily dose of 6 mg/kg.

89 patients were cured or improved with once-daily administration versus 90 patients with conventional administration. One patient in each group developed definite aminoglycoside-induced renal toxicity. The total cost [in 1993 Canadian dollars ($Can)] per patient for once-daily and conventionally administered aminoglycosides was $Can97.62 and $Can 199.43, respectively.

Thus, once-daily administration of aminoglycosides is as effective and well tolerated, while considerably less expensive than, aminoglycoside treatment utilising conventional regimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nordstrom L, Lerner SA. Single daily dose therapy with aminoglycosides. J Hosp Infect 1991; 18 Suppl. A: 117–29

    Article  PubMed  Google Scholar 

  2. Tulkens PM. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Agents Chemother 1991; 27 Suppl. C: 49–61

    Article  Google Scholar 

  3. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991; 35: 399–405

    Article  PubMed  CAS  Google Scholar 

  4. Zhanel GG, Ariano RE. Once daily aminoglycoside dosing: maintained efficacy with reduced nephrotoxicity? Ren Fail 1992; 14: 1–9

    Article  PubMed  CAS  Google Scholar 

  5. Hustinx WNM, Hoepelman IM. Aminoglycoside dosage regimens: is once daily enough? Clin Pharmacokinet 1993; 25: 427–32

    Article  PubMed  CAS  Google Scholar 

  6. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93–9

    Article  PubMed  CAS  Google Scholar 

  7. Craig WA, Vogelman B. The postantibiotic effect. Ann Intern Med 1987; 106: 900–2

    PubMed  CAS  Google Scholar 

  8. Mandell LA, Bergeron MG, Ronald AR, et al. Once-daily therapy with ceftriaxone compared with daily multiple-dose therapy with cefotaxime for serious bacterial infections: a randomized, double-blind study. J Infect Dis 1989; 160: 433–41

    Article  PubMed  CAS  Google Scholar 

  9. Health Sciences Association of British Columbia, Health Labour Relations Association of British Columbia. Master agreement 1 April 1992–31 March 1994. Vancouver: Health Sciences Association of BC

  10. Hospital Employees’ Union, Health Labour Relations Association of British Columbia. Master agreement 1991–1994. Vancouver: Hospital Employees’ Union

  11. Workload measurement systems. In: Guidelines for management information systems in Canadian health care facilities: diagnostic and therapeutic services — Pharmacy. Ottawa: Management Information Systems Project Steering Committee, 1985

  12. British Columbia’s Nurses’ Union, Health Labour Relations Association of British Columbia. Master collective agreement 1 April 1991–31 March 1994. Vancouver: British Columbia’s Nurses’ Union

  13. Vanhaeverbeek M, Siska G, Douchamps J, et al. Comparison of the efficacy and safety of amikacin once or twice-a-day in the treatment of severe gram-negative infections in the elderly. Int J Clin Pharmacol Ther Toxicol 1993; 31: 153–6

    PubMed  CAS  Google Scholar 

  14. Mailer R, Ahrne H, Eilard T, et al. Efficacy and safety of amikacin in systemic infections when given as a single daily dose or in two divided doses. J Antimicrob Chemother 1991; 27 Suppl. C: 121–8

    Article  Google Scholar 

  15. de Vries PJ, Verkooyen RP, Leguit P, et al. Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections. Eur J Clin Microbiol Infect Dis 1990; 9: 161–8

    Article  PubMed  Google Scholar 

  16. TerBraak EW, de Vries PJ, Bouter KP, et al. Once-daily dosing regimen for aminoglycosides plus (3-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990; 89: 58–66

    Article  CAS  Google Scholar 

  17. Sturm AW. Netilmicin in the treatment of Gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989; 159: 931–7

    Article  PubMed  CAS  Google Scholar 

  18. Beaucaire G, Leroy O, Beuscart C, et al. Clinical and bacteriological efficacy, and practical aspects of amikacin given once daily for severe infections. J Antimicrob Chemother 1991; 27 Suppl. C: 91–103

    Article  PubMed  Google Scholar 

  19. Marik PE, Lipman J, Kobilski S, et al. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients. J Antimicrob Chemother 1991; 28: 753–64

    Article  PubMed  CAS  Google Scholar 

  20. Prins JM, Buller HR, Kuijper EJ, et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335–9

    Article  PubMed  CAS  Google Scholar 

  21. McCormack JP, Jewessen PJ. A critical reevaluation of the ‘therapeutic range’ of aminoglycosides. Clin Infect Dis 1992; 14: 320–39

    Article  PubMed  CAS  Google Scholar 

  22. Konrad F, Wagner R, Neumeister B, et al. Studies on drug monitoring in thrice and once daily treatment with aminoglycosides. Intensive Care Med 1993; 19: 215–20

    Article  PubMed  CAS  Google Scholar 

  23. Brown G, McCormack JP. Monitoring of aminoglycosides [letter]. Intensive Care Med 1993; 19: 243

    Article  Google Scholar 

  24. Hitt CH, Klepser ME, Nightingale CH, et al. Pharmacoeconomic impact of a once-daily aminoglycoside program [abstract]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17–20; San Francisco, 348

    Google Scholar 

  25. Amaya-Diaz A, Okpara A, Egunike I, et al. Evaluation of efficacy and nephrotoxicity associated with once daily dosing of aminoglycosides [abstract]. American Society of Hospital Pharmacists Midyear Clinical Meeting, 1994 Dec 4–8; Miami Beach, 398

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 12th and Oak Pavilions, Vancouver, British Columbia, Canada

    Hanif Mithani

  2. Pharmacy Department, St Paul’s Hospital, 1081 Burrard Street, Vancouver, British Columbia, V6Z 1Y6, Canada

    Glen Brown

Authors
  1. Hanif Mithani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Glen Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Glen Brown.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mithani, H., Brown, G. The Economic Impact of Once-Daily versus Conventional Administration of Gentamicin and Tobramycin. Pharmacoeconomics 10, 494–503 (1996). https://doi.org/10.2165/00019053-199610050-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199610050-00007

Keywords

Search

Navigation